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ABSTRACT
Introduction: Fluocinolone acetonide (FAc)
intravitreal implant (ILUVIEN; Alimera
Sciences Limited, Aldershot, UK) has been
approved in the UK for the treatment of
chronic diabetic macula edema, insufficiently
responsive to available therapies. It is inserted
into the vitreous cavity through a 25-gauge
needle. Migration of the implant to the anterior
chamber (AC) can occur through gaps in the
posterior capsule especially in vitrectomized
eyes. Early removal of AC-dislocated FAc
implant is essential to prevent corneal edema
and damage from raised intraocular pressure.
Aim: To demonstrate a simple and novel
technique, with a previous capsular tear, for
removal of AC-migrated FAc implant and
reinsertion into the vitreous cavity without
compromising implant integrity.
Method: A side port incision was created with a
keratome and an anterior chamber maintainer
introduced and secured. Subsequently, a
corneal incision was created at 12 o’clock
through which a 23-gauge backflush needle
(flute needle) was advanced into the anterior
chamber and passive suction used to secure the
implant. The flute needle was then placed
through the defect in the posterior capsule
and the exit port blocked, causing loss of
suction and allowing the implant to fall into
the posterior segment. The sulcus intraocular
lens (IOL) was centralized simply by
manipulating it approximately 180 degrees to
provide adequate anterior capsule support.
Results: The FAc implant was successfully
removed from AC in two patients and
reinserted into the vitreous cavity without
damage or complications either for the eye or
the implant. IOL in both patients were
repositioned to close the gap in posterior
capsule. After 2 months, the implant remains
in the vitreous cavity. This paper presents data
from one of these cases.
Conclusion: Using 23-gauge flute needle to
retrieve dislocated FAc implant is a safe and
easy technique.
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INTRODUCTION
A 74-year-old male with a 24-year history of
Type 2 diabetes developed chronic diabetic
macula edema in his right eye. Previous
therapies included macular grid laser and
intravitreal avastin for diabetic macula edema.
He had phacoemulsification complicated by
posterior capsule rupture and loss of a nucleus
fragment into the posterior segment. He
subsequently underwent 23-gauge pars plana
vitrectomy and removal of lens fragment,
followed by sulcus placement of an intraocular
lens.
At his 1-month post-operative visit, the right
visual acuity was 6/60 and intraocular pressure
was 22 mmHg. Slit lamp examination revealed a
slightly inferiorly displaced intraocular lens and
on optical coherence tomography (OCT); his
central macula thickness was 619 lm. He
underwent monthly intravitreal Lucentis
injections over 4 months, but his macula
edema persisted, with no improvement in
visual acuity. At this time, the decision was
made to proceed with insertion of the
fluocinolone acetonide intravitreal (FAc)
implant (ILUVIEN; Alimera Sciences Limited,
Aldershot, UK), which was performed without
complication as an outpatient procedure.
He was reviewed in the clinic 13 days later
and the right visual acuity was 6/36 and central
macular thickness was 517 lm. However, slit
lamp examination revealed the FAc implant
lying horizontally in the inferior angle of the
anterior chamber (Fig. 1). Intraocular pressure
was 30 mmHg and there was no associated
corneal edema.
METHOD USED TO REPOSITION
THE MIGRATED IMPLANT
Five days later, the patient was taken to the
operating room. (Please see the video for case 1
in the supplementary material.) A side port
incision was created with a keratome and an
anterior chamber maintainer introduced and
secured (Fig. 2). Subsequently, a corneal
incision was created at 12 o’clock through
which a backflush needle (flute needle) was
advanced into the anterior chamber and passive
suction used to secure the intact implant
(Fig. 3). The flute needle was then placed
through the defect in the posterior capsule
and the exit port blocked, causing loss of
suction and allowing the implant to fall into
the posterior segment. The sulcus intraocular
lens (IOL) was centralized simply by rotating it
approximately 180 degrees to provide adequate
anterior capsule support (Fig. 4). Three weeks
post-operatively, the patient’s visual acuity was
6/60, the IOL is centrally placed, intraocular
pressure (IOP) is 17 mmHg, the cornea remains
clear and the FAc implant remains in the
Fig. 1 Migrated ILUVIEN implant in the inferior angle
of anterior chamber
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posterior segment. This outcome remained
stable after 1 year of follow-up.
Informed consent was obtained from the
patient for being included in this study.
DISCUSSION
FAc implant is a non-biodegradable cylindrical
tube (measuring 3.5 9 0.37 mm) of polyimide
loaded with 190 micrograms of FAc that is
inserted into the vitreous cavity through a
25-gauge needle in an outpatient setting [1].
The FAc implant has been approved by the
United Kingdom National Institute for Health
and Care Excellence (NICE technology appraisal
TA301) for people with chronic diabetic
macular edema (DMO) who have an artificial
lens in their eye if: the implant is used in the eye
with the artificial lens; and, their DMO has not
responded sufficiently to other treatments [2].
To our knowledge, this is the first reported
case of anterior chamber migration of the FAc
implant. Multiple cases of anterior migration of
the intravitreal dexamethasone implant
(Ozurdex; Allergan Pharmaceuticals Ireland,
Westport, Ireland) have been reported in the
literature [3–5]. The importance of prompt
removal of the anteriorly migrated
dexamethasone implants was emphasized by
Khurana et al. [6] in their recently published
series of 18 episodes (15 patients) with anterior
migration of the dexamethasone implant. In
their series, 89% of cases developed corneal
edema, with keratoplasty recommended in 43%
for non-resolving corneal edema after removal
of the dexamethasone implant. They also
identified previous vitrectomy and an absent
or compromised posterior capsule (factors
which are present in our case) as risk factors
for anterior migration. Khurana et al. also
described unsuccessful attempts to grasp the
implant with tying forceps and intraocular
forceps in some cases, resulting in
disintegration of the implant into smaller
pieces.
In our report, we describe a novel technique
for surgical removal and repositioning. The
Fig. 2 Anterior chamber maintainer in the anterior
chamber, superior gap in posterior capsule and inferior
displacement of the intraocular lens
Fig. 3 ILUVIEN implant inside the tip of ﬂute needle
and redirected to vitreous cavity through the gap in
posterior capsule
Fig. 4 Centralized intraocular lens after repositioning and
covering posterior capsule
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flute needle devised by Dr. Steve Charles
(Memphis, USA) is an invaluable tool used for
various posterior segment procedures. This
includes simultaneous exchange of intraocular
fluid for air, a gas/air mixture or silicone oil,
internal drainage of subretinal fluid through a
hole in the retina and manipulation of a giant
retinal tear. It consists simply of a blunt-ended
needle (available in various gauge sizes)
connected by a Luer fitting or Luer lock to a
handle.
Within the handle, an internal channel
connects the Luer terminal to an exit port in a
depression on the side of the handle. When the
needle is introduced into the vitreous cavity via
a pars plana sclerotomy, closure of the exit port
by the surgeon’s finger prevents flow of fluid or
gas from the eye. Removal of the finger allows
egress of fluid along the needle and through the
exit hole, provided an infusion of gas or fluid
maintains the intraocular pressure above
atmospheric pressure. Using the same
principles, the flute needle can be used in the
anterior chamber, in our case as a suction/
aspiration device to grasp and reposition the
FAc implant.
We used a 23-gauge backflush/flute needle,
which allowed easy grasp of the FAc implant.
For a dexamethasone implant, a 20-gauge
needle would be appropriate. This technique is
quick, requires minimal manipulation or tissue
disturbance and allows for easy repositioning of
the implant, if desired. The non-biodegradable
nature of the FAc implant allowed
manipulation and repositioning without the
implant breaking into pieces.
While corneal decompensation has been
described in association with anterior
migration of the dexamethasone implant and
Retisert insert (containing 0.59 milligrams of
FAc [7]; Bausch & Lomb, Rochester, NY, USA),
this did not occur in our patient. We postulate
that this is as a result of prompt repositioning of
the implant, the smaller size of the FAc implant
compared to the dexamethasone implant
(which is 0.46 mm in diameter and 6 mm in
length [8]) or a combination of both factors.
However, there are reports of the drug-eluting
portion of the Retisert insert (which is 1.5 mm)
dislocating into the anterior chamber and
causing corneal edema [9]. As non-resolving
corneal edema is a potential risk [10], prompt
removal is advocated in these cases.
Of note, there was resolution of intraocular
pressure back to normal limits after removal of
the implant. Reports suggest that placement of
steroid implants closer to the trabecular
meshwork or ciliary body results in a higher
incidence of raised intraocular pressure [7].
CONCLUSION
In conclusion, we describe a case of a FAc
implant dislocation and a novel technique for
ease of removal from the anterior chamber of
the eye. Early removal is essential to prevent
corneal edema and damage from raised
intraocular pressure. Caution should be
employed when deciding to inject the FAc
implant in the eye with posterior capsule
defects and when anterior migration occurs,
we recommend repositioning into the vitreous
cavity with a backflush/flute needle as a
straightforward technique.
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